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Abstract  22 
Objectives: To assess how nausea and vomiting in pregnancy (NVP) and hyperemesis gravidarum 23 
(HG) are managed and treated across primary and secondary care. 24 
Design: Population-based pregnancy cohort 25 
Setting: Medical records (CPRD-GOLD) from England 26 
Population: 417,028 pregnancies, during 1998-2014  27 
Methods: Proportions of pregnancies with recorded NVP/HG diagnoses, primary care treatment and 28 
hospital admissions were calculated.  Multinomial logistic regression was employed to estimate 29 
adjusted relative risk ratios (aRRRs) with 99% confidence intervals (CIs) for the association between 30 
NVP/HG management paths and maternal characteristics. 31 
Main Outcome Measures: NVP/HG diagnoses, treatments and hospital admissions.  32 
Results: Overall prevalence of clinically recorded NVP/HG was 9.1%:  2.1% had hospital 33 
admissions, 3.4% were treated with antiemetics in primary care  only, and 3.6% had only recorded 34 
diagnoses. Hospital admissions and antiemetic prescribing increased continuously during 1998-2013 35 
(trend p<0.001). Younger age, deprivation, Black/Asian/Mixed ethnicity, multiple-pregnancy were 36 
associated with NVP/HG generally across all levels, but associations were strongest for hospital 37 
admissions. Most comorbidities had patterns of association with NVP/HG levels. Among women with 38 
NVP/HG who had no hospital admissions, 49% were prescribed antiemetics, mainly from first line 39 
treatment (21% prochlorperazine, 15% promethazine, 13% cyclizine) and metoclopramide (10%).  Of 40 
those admitted, 38% had prior antiemetic prescriptions (34% first-line, 9% second-line, 1% third-line 41 
treatment). 42 
Conclusion: Previous focus on hospital admissions has greatly underestimated the NVP/HG burden. 43 
Although primary care prescribing has increased, most women admitted to hospital have no 44 
antiemetics prescribed before this. An urgent call is made to assess whether  admissions could be 45 
prevented with better primary care recognition and timely treatment. 46 
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Introduction   70 
Although nausea and vomiting is a very common symptom in pregnancy (NVP), affecting up to 70% 71 
of women 1 who often do not require treatment, in some cases severity can reach critical levels 72 
requiring hospital admission and need for continuous monitoring 2. This severe condition, referred to 73 
as hyperemesis gravidarum (HG), has a reported prevalence of around 1.1% worldwide 1 and is 74 
responsible for a range of complications due to malnutrition, dehydration and excessive weight loss. 75 
Maternal and child health are affected by possible adverse effects of HG 3–5 and pregnancy 76 
complications are more likely 6. These sequelae havesubstantial financial impact on the health 77 
services and significant burden on professional health care provision 7–9.  78 
In June 2016, the Royal College of Obstetricians and Gynaecologists (RCOG) published the first 79 
national guidelines on the clinical management of NVP and HG for the United Kingdom (UK) 10 80 
providing an accurate handbook for controversial decision making processes in the management of 81 
this condition with prescribed medications. Although this is supported by international reviews of HG 82 
11–13, there is no published evidence of how this condition is actually managed by health professionals 83 
and what common clinical pathways are followed by affected women. In the UK, research based on 84 
surveys 14,15 have shown general dissatisfaction with current clinical care from women experiencing 85 
HG, with a claim that many hospital admissions could have been avoided had they received timely 86 
antiemetic prescribing to curtail worsening severity. It is unknown whether under-prescribing or late 87 
recognition of NVP and HG is widespread as there are no population-based studies showing how this 88 
condition is managed between primary and secondary care. 89 
Using the Clinical Practice Research Datalink database (CPRD-HES), we have assessed thespectrum 90 
of NVP and HG across primary and secondary care and described how severity and pathways of 91 
management vary by maternal and pregnancy characteristics and comorbidities. We assessed the 92 
extent to which women are prescribed antiemetics in primary care and how this relates to hospital 93 
admissions. 94 
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Materials and Methods   95 
Data source 96 
We used primary and secondary care health records linked at individual patient level from the Clinical 97 
Practice Research Datalink (CPRD GOLD),16 which includes over 15 million patients from 684 98 
general practices (GP) across the UK 17. Recorded information consists of demographics, symptoms 99 
and diagnoses coded using the Read coding system 18, clinical tests and drug prescriptions. Over half 100 
of CPRD GOLD patients are linked with the Hospital Episodes Statistics (HES) database 19 which 101 
consists of all admissions to English hospitals. Information within HES includes diagnoses coded 102 
using the International Classification of Diseases system (ICD-10)21 and hospital procedures coded 103 
using the Office of Population Censuses and Surveys Classification of Interventions and Procedures 104 
(OPCS-4)22. Maternity data contained in HES includes extensive information on pregnancy, labour 105 
and delivery; it is the main datasource for monitoring maternity statistics in England23 and is used to 106 
for perinatal epidemiology research 23,24. Our previous studies using the CPRD-HES linked population 107 
show maternities are representative of those across the English population25,26. Patients were not 108 
involved in the development of the research. 109 
Study population  110 
Women with pregnancies ending in live birth or stillbirth between October 1998 and April 2014 who 111 
had active primary care registration were selected by extracting information from GP and HES 112 
records (operational codes of delivery) to obtain the most complete and precise information on each 113 
pregnancy. For live births, a probabilistic matching algorithm was employed to link each mother’s 114 
pregnancy records to the corresponding children by matching each delivery date to a child’s estimated 115 
birth date or HES birth admission and ensuring they had matching a household code, a unique 116 
identifier indicating which individuals in each practice live together. Gestation and pregnancy details 117 
were extracted from HES maternity data and, when missing, from the child’s HES birth record, the 118 
mother’s or child’s GP records in this order of priority.  119 
6 
 
Diagnoses and hospital admissions for NVP and HG 120 
To capture the full spectrum of severity, as defined in the national guidelines10, we identified all 121 
primary care diagnoses and hospital admissions for NVP/HG during pregnancy, using specific Read 122 
codes for primary care (Table S1) and ICD-10 codes for secondary care (Table S2) that were 123 
approved by co-author CNP who is a consultant in obstetric medicine. Due to controversy over a true 124 
distinction between NVP and HG and the lack of a standard approach for the diagnosis and clinical 125 
management of these conditions 4, the risk that these diagnoses could have been used interchangeably 126 
by health professionals to refer to the same condition was taken in to consideration by carrying out a 127 
comprehensive analysis considering both diagnoses.   128 
To exclude presentations of nausea and vomiting for specific reasons, a restrictive criterion was 129 
applied excluding any NVP diagnoses with evidence of differential diagnoses (Table S3 and S4) 130 
recorded in GP data from one week before up to one week after the NVP diagnosis date or in HES 131 
data as a secondary reason of admission. This resulted in 1.9% of GP consultations and 17.6% of 132 
hospital admissions for NVP being excluded.  133 
Drug treatment for NVP and HG 134 
Antiemetic prescriptions were extracted from primary care records using selected drugs codes (Table 135 
S5) according to national recommendations from the RCOG,10 and grouped in the following drug 136 
classes: antihistamines, phenothiazine dopamine antagonists, serotonin antagonists and steroids. As 137 
some drugs have multiple indications, differential diagnostic indications were explored to ensure the 138 
drugs under analysis were prescribed for the purpose of treating NVP/HG, according to the British 139 
National Formulary (BNF) 27.  140 
Grouping women with NVP/HG by their clinical management pathway 141 
We categorised women into 4 mutually exclusive groups (Figure 1), broadly representing their level 142 
of NVP/HG burden, according to their presentation and treatment in primary care or occurrence of 143 
hospital admissions as follows: a primary care diagnosis only, treatment in primary care, early 144 
hospital admissions (>=20 weeks gestation), late hospital admissions. We compared these four groups 145 
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to a control group of all remaining women, i.e. those with no evidence of NVP/HG diagnosis nor 146 
treatment. 147 
Maternal characteristics 148 
We assessed maternal characteristics and comorbidities based on their previous evidence as risk 149 
factors for NVP/HG 28,29 and information currently available in the CPRD-HES source dataset. These 150 
were: maternal age at delivery, socioeconomic deprivation as measured by the Index of Multiple 151 
Deprivation (IMD 2010) in quintiles 30, ethnicity, smoking status during pregnancy, parity, birth 152 
plurality, diabetes, hypertension, pre-eclampsia, parathyroid dysfunction, coronary heart diseases, 153 
anaemia, thyroid dysfunction, hypercholesterolemia and asthma.  154 
Statistical analysis 155 
Numbers and proportions of pregnancies for each NVP/HG group (i.e. diagnosis only, antiemetic 156 
treatment, early hospital admission and late hospital admission) were presented overall and the change 157 
in prevalence of each group was shown over time. To assess whether maternal characteristics differed 158 
by NVP/HG group, we used multinomial logistic regression (mlogit31 with rrr option) to estimate 159 
relative risk ratios (RRR) with 99% confidence intervals (CI) for the association of each level of 160 
NVP/HG burden with maternal characteristics/comorbidities, compared to the control group. RRRs 161 
were adjusted for all the maternal characteristics and pre-existing comorbidities available in the data 162 
except for the risk factor of interest (Table 1). In order to account for potential clustering effects from 163 
including mothers with more than one pregnancy, a cluster option was set in the analysis. Missing 164 
values, present only for three maternal characteristics, namely ethnicity (12.4% missing), smoking 165 
(27.8%) and deprivation status (0.2%), were imputed using the multinomial logistic regression 166 
imputation method available in Stata MPv15 (Stata Corp, College Station, TX) statistical package 32, 167 
applying the mi imp mlogit function31, setting 10 imputed datasets and using all maternal 168 
characteristics available as predictor variables.As a sensitivity analysis to assess whether clear clinical 169 
distinctions were actually being made between NVP and HG diagnoses, we conducted stratified 170 
analyses by 1) dividing the primary care diagnosis only group into a) those with HG diagnoses and b) 171 
those with only NVP diagnoses, and 2) dividing the primary care treatment group into those with a) 172 
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antiemetics prescribed for an HG indication and b) antiemetics prescribed for an NVP indication only. 173 
We assessed the prevalence of these four groups over time and whether they varied by maternal 174 
characteristics.  175 
Results 176 
Within the study period there were 417,028 deliveries ending in live births or stillbirths in 300,858 177 
women. The prevalence of NVP/HG overall was 9.1% (37,856): 3.6% (14,815) pregnancies with 178 
primary care diagnoses that did not obtain treatment, 3.4% (14,226) with primary care diagnoses that 179 
were administered antiemetic drug treatment, 1.5% (6,390) with first hospital admission before 20 180 
weeks and 0.6% (2,425) with late hospital admissions from 20 weeks onwards. Between 1999 and 181 
2013 (Figure 2) there were statistically significant increases in early hospital admissions and 182 
antiemetic prescribing such that by 2013, early admissions occurred in 2.1% of pregnancies and 183 
antiemetics were prescribed in primary care in 5.2% of pregnancies compared with 2.5% of 184 
pregnancies with recognised NVP/HG that were left untreated (p<0.001 for both). 185 
Management variation by maternal characteristics 186 
Maternal characteristics varied across the groups (Table 1). In general, compared with control 187 
pregnancies, those among women with NVP/HG had higher proportions of younger women, with 188 
higher socioeconomic deprivation, or with Asian or Black ethnicity, and these proportions increased 189 
with level of NVP/HG burden with the highest among women with hospital admissions. The 190 
prevalence of comorbidities was generally higher in the affected groups compared with control 191 
pregnancies, particularly for pre-existing diabetes, gestational hypertension, pre-eclampsia, 192 
gestational anaemia and thyroid dysfunctions, asthma, and hypercholesterolemia. 193 
In the adjusted analysis (Table 1), results showed a clear increased risk of NVP/HG with younger 194 
maternal age across all levels of burden with the magnitude of risk highest for hospital admissions; 195 
whilst women under 25 years were 1.5 times as likely to be treated in primary care compared with 196 
women age 30-34 years, they were over twice as likely to be admitted to hospital. Women from more 197 
deprived socio-economic groups had a comparable prevalence of NVP/HG diagnoses, however they 198 
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were more likely to be treated with antiemetics in primary care, and to have early hospital admission 199 
compared with women from the least deprived group (test for trend p<0.001 for all groups other than 200 
diagnosis only). Asian and Black women had considerable increased risks across all levels of 201 
NVP/HG burden, although there was no association between ethnicity and late hospital admission. 202 
Current smoking was associated with a decreased risk of NVP/HG across all levels other than late 203 
hospital admissions. There was no association with multiparity other than a decreased risk in primary 204 
care diagnosis of NVP/HG only. Multiple birth was associated with NVP/HG diagnosed and treated in 205 
primary care but the risk was highest in those with early hospital admissions. 206 
Diabetes and hypertension were not associated with NVP/HG diagnosed or treated in primary care, 207 
although they were associated with some increase in late NVP/HG hospital admissions and pre-208 
existing diabetes increased the risk of early hospital admissions. Pre-eclampsia was associated with 209 
women treated for NVP/HG in primary care, while eclampsia was associated with NVP/HG diagnoses 210 
and late hospital admissions.  Asthma and anaemia increased the risk of all levels of NVP/HG. There 211 
was an increased risk of primary care treatment and hospital admissions in women with thyroid 212 
dysfunction or hypercholesterolemia. 213 
Antiemetic prescribing distribution 214 
Distributions of primary care antiemetic prescribing for women with NVP/HG who were and were not 215 
admitted to hospital are shown in Table 2. Of those never admitted to hospital (29,041), antiemetics 216 
were prescribed in 49% of pregnancies; first, second and third-line treatment was prescribed for 42%, 217 
11%, and 1% of pregnancies respectively. The most commonly prescribed antiemetic was 218 
prochlorperazine (21.1%), followed by the other first line drugs promethazine (15.4%) and cyclizine 219 
(13%). While ondansetron and steroids were very rarely prescribed to these women, metoclopramide 220 
was the most commonly prescribed second line treatment (10%) followed by domperidone (1.5%). 221 
Of the 6,390 pregnancies with early NVP/HG hospital admission (1.5% overall), only 38% had 222 
evidence of a primary care prescription of antiemetics before the admission and 50% had antiemetics 223 
prescribed following the admission. Overall, 34% received first-line treatment before admission, 9% 224 
second-line and 1% third-line treatment. Individual drugs prescribed were similar to those for 225 
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unadmitted women, with prochlorperazine being the most common first-line and metoclopramide the 226 
most common second-line treatment. Following admissions, cyclizine, metoclopramide and 227 
prednisolone prescription rates doubled compared to pre-admission rates and ondansetron increased 228 
from 0.4% pre-admission to 4.6% post-admission, reflecting the follow on from the higher level of 229 
treatment lines prescribed in secondary care. 230 
Women with late admissions from 20 weeks gestation onwards had even lower prescribing of 231 
antiemetics before their first admission (23% of pregnancies treated pre-admission) and only 8% had 232 
antiemetics prescribed post-admission. First-line treatment was prescribed in 18% of pregnancies pre-233 
admission, with second and third-line treatment prescribed in 6% and 2% respectively. 234 
Prochlorperazine was still the most common drug prescribed pre-admission, followed by cyclizine, 235 
metoclopramide and promethazine. 236 
Sensitivity analysis distinguishing NVP from HG diagnoses made in primary care 237 
Among women with recognised NVP/HG who were never admitted to hospital, the proportions of 238 
pregnancies receiving an HG diagnosis (rather than an NVP diagnosis) were 21% of those without 239 
drug treatment and 41% of those with drug treatment. These proportions remained constant over time 240 
(Figure S1) indicating that NVP and HG diagnoses may have been used interchangeably in the 241 
medical records. Furthermore, the distribution of key maternal characteristics and comorbidities were 242 
very similar between those with HG diagnosed and those with only NVP diagnosed (Figure S2 and 243 
Table S6) again providing the rationale for NVP/HG being considered as the same clinical group. 244 
 245 
Discussion    246 
Main findings 247 
We found that 9.1% of pregnancies had NVP/HG that was clinically recognised in primary or 248 
secondary care; 7% did not result in hospital admission but was treated by GPs with antiemetics half 249 
of the time, and 2.1% resulting in hospital admissions. 38% of women admitted to hospital had 250 
received previous antiemetics in primary care. The prevalence of affected women prescribed 251 
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antiemetics in primary care has increased over time with a turning point at 2008 after which affected 252 
women were more likely to be treated than not. Hospital admissions, however, also increased over 253 
time, showing an overall increase in the recognised clinical burden of NVP/HG. Moreover, NVP and 254 
HG diagnoses were used in a similar way both for antiemetic prescribing and hospital admissions, 255 
likely reflecting health professionals considering them on a spectrum of illness, despite distinguishing 256 
clinical criteria for hyperemesis gravidarum diagnosis. 257 
Strengths and limitations 258 
The CPRD-HES is a well validated data source 33 widely used for epidemiological research34 , broadly 259 
nationally representative17,35.and internationally recognised as an extremely meaningful source of 260 
clinical information for studying pregnancy complications and prescribed treatments in England. 261 
To our knowledge, this is the first large epidemiological study evaluating the prevalence of clinically 262 
recognised and managed NVP/HG within primary and secondary care. 263 
One of the major strengths of this study was the possibility to assess the antiemetic treatments offered 264 
to women with NVP/HG in primary care. However, secondary care prescribing was not available and 265 
although discharge prescriptions are usually short supply, results on prescribing after admission need 266 
to be interpreted cautiously. Whilst it is possible that we overestimated treatments used for NVP/HG, 267 
considering antiemetics have multiple indications, we think this is unlikely as we assessed differential 268 
diagnoses for each consultation where antiemetics were prescribed and carefully excluded 269 
prescriptions referred for treating other conditions including corticosteroids used for asthma, Crohn’s 270 
disease and other auto-immune conditions. Some antihistamines are available without prescription, 271 
however, we do not think this underestimated prescriptions as no antiemetics  were  licensed for use 272 
in pregnancy in England during the study period and pregnant women receive free prescriptions from 273 
the GP. We also applied rigorous exclusion criteria for NVP diagnoses that had differential diagnoses 274 
for these symptoms, such as gastrointestinal, metabolic or genitourinary conditions, as indicated in 275 
RCOG national guidelines for NVP/HG( RCOG, 2016). We acknowledge that NVP is a common 276 
symptom in many diseases and potentially also attributable to other conditions such as diabetes or pre-277 
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eclampsia, however, as these are not differential diagnoses, it is also possible that there is co-existence 278 
of NVP/HG with other comorbidities.   279 
We have included an extensive analysis of risk factors, however, results could have been affected by 280 
residual confounding as we did not include certain factors such as BMI or family support which were 281 
not comprehensively recorded in the data and there was sub-optimal recording of certain 282 
demographics or life style factors such as ethnicity or smoking status. However quality of data has 283 
improved over time 35 and robust information on pre-existing comorbidities and pregnancy 284 
complications was available 33. Moreover imputation of missing values for the affected variables was 285 
used to minimise this limitation.  286 
We have included women firstly admitted for NVP/HG after 20 weeks of gestation and although the 287 
classic presentation of HG is a hospital admission prior to 20 weeks 36, some women remain 288 
symptomatic throughout pregnancy 37 so it was important to capture this group, who may represent a 289 
severe and sustained burden of HG. However we acknowledge that those women could have been 290 
admitted for excessive NVP due to other underlying conditions such as diabetes, gestational 291 
hypertension, eclampsia or hypercholesterolemia, revealed to be strong risk factors of late admissions. 292 
It is important to acknowledge that our findings represent the clinical prevalence of NVP/HG in 293 
pregnancies ending in live and stillbirths only, as we did not include pregnancies ending in 294 
spontaneous or non-spontaneous abortion. Although some studies have indicated that HG can lead to 295 
pregnancy terminations38, more research is needed to assess how severe NVP and HG may relate to 296 
both early or late pregnancy losses. 297 
Interpretation 298 
We have shown that the actual prevalence of clinically recognized NVP/HG is higher than previously 299 
reported in agreement with a recently published study based oneight English primary care settings. 39 300 
Using the linked CPRD-HES data source we have been able to provide this important missing 301 
information to complete the picture of NVP and HG management. Most of the current literature that 302 
describes the prevalence of HG or NVP is either based on medical records of hospital admissions 28,40–303 
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42 or questionnaires filled in by the affected women to assess the severity of symptoms in an attempt to 304 
detect the actual occurrence of HG or NVP, for which women may not always consult a healthcare 305 
professional 9,43–45.  We found that overall, HG was diagnosed and managed in primary care  alone in 306 
2.5% of pregnancies , of which 75% were treated with antiemetics, showing an higher HG burden 307 
than previously reported figures. 308 
In our study the level of NVP/HG burden varied by maternal characteristics and comorbidities 309 
consolidating the current knowledge 29 that young mothers, women of Black and Asian ethnic origin, 310 
those from more deprived socioeconomic groups, and with multiple pregnancies are generally more 311 
likely to be affected across the whole severity spectrum. In particular, women from more deprived 312 
backgrounds were much more likely to be admitted to hospital, slightly more likely to be treated with 313 
antiemetics, but had similar risk of diagnosis-only to women from less deprived backgrounds, 314 
indicating that earlier treatment may prevent later hospital admissions.   315 
An Australian review 46 revealed the suboptimal management offered to women affected by NVP was 316 
due to the lack of national standard guidelines, concerns about drug teratogenicity and 317 
underestimation of the impact of NVP on women’s lives. A pregnancy Sickness Support survey 318 
recently published in the UK also reported significant problems accessing treatment and high levels of 319 
dissatisfaction with care. 14 General failure of an appropriate HG treatment provision was reported 320 
nationally 15,47,48 and internationally 49 with a consequent feeling of isolation and dissatisfaction among 321 
the affected women, exacerbated by further evidence of lack of high-quality studies to support any 322 
particular intervention. 50 Despite a general consensus that some women are denied access to 323 
antiemetics that could help relieve the severe symptoms of these conditions 47, we found that use of 324 
antiemetics in pregnancy has increased over time. This could be a sign of rising awareness of the 325 
impact of these conditions on the quality of life together with a growing confidence in GPs’ 326 
prescribing, supported by growing evidence for the safety of antiemetics in pregnancy 10.  However, 327 
we also found that women with early hospital admissions were much less likely to be treated in 328 
primary care before their admission compared with women who never experienced hospital 329 
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admissions (38% versus 49%), potentially supporting the hypothesis that some hospital admissions 330 
may be preventable with timely treatment.  331 
Conclusions  332 
The actual burden of clinically recognised NVP/HG is larger than reported figures, currently affecting 333 
almost 10% of pregnancies due to a proportion of women reporting clinically relevant symptoms that 334 
are managed at primary care level, half of which are treated with antiemetics. Higher NVP/HG 335 
severity levels generally confirm the consolidated knowledge of which women are more at risk of 336 
developing this condition, with no relevant differences between NVP and HG diagnosis. Doctors’ 337 
confidence in prescribing antiemetic drugs to pregnant women is increasing, although 62% of women 338 
with hospital admissions were not prescribed an antiemetic, raising urgent calls to clarify whether 339 
optimal and timely treatments could help prevent hospital admissions. 340 
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